|
Axelopran (INN, USAN) (developmental code name TD-1211) is a drug which is under development by Theravance Biopharma for the treatment of opioid-induced constipation. It acts as a potent, selective, and peripherally-restricted μ-, κ-, and δ-opioid receptor antagonist, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Axelopran has potent μ-opioid receptor antagonist activity on the gastrointestinal tract ''in vivo'', and thus it produces a dose-dependent inhibition of opioid-induced delaying in gastric emptying in mice and rats following subcutaneous or oral administration.〔(), AXELOPRAN (TD-1211) BRIEFING DOCUMENT ANESTHETIC AND ANALGESIC DRUG PRODUCTS ADVISORY COMMITTEE JUNE 11 AND 12, 2014.〕 ==See also== * Alvimopan * Eluxadoline * Methylnaltrexone * Naldemedine * Naloxegol 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Axelopran」の詳細全文を読む スポンサード リンク
|